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Background: Understanding the integration of hormone signaling and how it impacts oncogenesis is critical for
improved cancer treatments. Here we elucidate GNAI2 message alterations in ovarian cancer (OvCa). GNAI2 is a
heterotrimeric G protein which couples cell surface hormone receptors to intracellular enzymes, and is best
characterized for its direct role in regulating cAMP response element-binding protein (CREB) function by decreasing
intracellular cAMP through inhibiting adenylyl cyclase.
Methods: We probed the Origene human OvCa array for the presence of polymorphisms and gene expression
alterations of GNAI2 using directing sequencing and qPCR. These data were supported by database mining of the
[NCBI NIH GSE:6008, GSE:14764, GSE:29450, GDS:4066, GDS:3297, GSE:32474, and GSE:2003] datasets.
Results: No significant polymorphisms were found, including an absence of the gip2 oncogene. However, 85.9% of
(506 of 589) OvCa patients had decreased GNAI2 message. Further characterization demonstrated that the GNAI2
message was on average decreased 54% and maximally decreased by 2.8 fold in clear cell carcinoma. GNAI2
message decreased in early stage cancer while message was increased compared to normal in advanced cancers.
The changes in GNAI2 also correlated to deregulation of CREB, Fos, Myc, cyclins, Arf, the transition from estrogen
dependence to independence, and metastatic potential.
Conclusion: These data strongly implicate GNAI2 as a critical regulator of oncogenesis and an upstream driver of
cancer progression in OvCa.
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Elucidation of the conserved molecular pathologies lead-
ing to ovarian cancer (OvCa) initiation and progression
are of great interest for targeted therapies. Most OvCa
patients present with advanced and metastatic forms
and little is known about the early pathophysiology lead-
ing to this widespread disease [1]. In the ovary there are
multiple specialized cellular and histologic types which
are often grouped together for simplicity, but represent
several distinct cancers which have both conserved and
unique susceptibilities to oncogenesis and therapeutics.
The majority of ovarian cancers are epithelial in origin,
including serous, endometrial, mucinous, and clear cell
carcinomas [2,3]. Papillary serous tumors are the most
common and thought to be mediated through p53 mu-
tations and loss of BRCA with possible origination in* Correspondence: petersy@musc.edu
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stated.the fallopian tube. Endometrioid carcinomas are pleio-
tropic and can be either estrogen receptor (ER) positive
or negative, and display variable alterations in p53,
PTEN, Ras, and E-cadherin [4]. Clear cell ovarian cancer
represents ~5% of cases. Clear cell tumors often have
normal p53 but decreased ER and CD44 and present
more frequently in patients with a personal or family
history of endometriosis [3]. Mucinous tumors make up
about 10% of cases and also frequently show p53 muta-
tions, but are most distinct by acquiring frequent KRAS
alterations and secreting estrogen [5]. The diversity of
specific types of cancer and potential mechanisms indi-
cates a critical need to identify conserved upstream regula-
tors that also function as integrators of multiple signaling
inputs.
In recent years, G protein coupled receptors (GPCRs)
signaling cascades have come to light as primary media-
tors of oncogenic signaling by playing critical roles in in-
flammation, transformation, invasion, and metastasis [6,7].
Overactive signaling at the level of hormones, receptors,
or G protein can initiate and potentiate cancer [8-11].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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has pleotropic effects in regulating cellular viability and
migration. A large number of vital hormones including
epinephrine, dopamine, acetylcholine, somatostatin, angio-
tensin, and sphingosine-1-phosphate signal through the
Gαi pathway [12]. Gαi is best described as being the inhibi-
tory isoform of Gα that suppresses adenylate cyclase ac-
tivity leading to decreased cAMP accumulation [13-15].
However, Gαi is also known to regulate many other effec-
tors including Src, ERK1/2, phospholipase-C, and mono-
meric GTPase’s like Rap [10,16-22]. For example, LPA
stimulation of Gαi2 leads to activation of Src and Rac
which is critical for invasive migration of ovarian cancer
cells [23]. Indicative of a conserved mechanism, Gαi2 is
also critical for migration in prostate, macrophage, and
neutrophil cells [10,24].
OvCa specific alterations in GNAI2 have been de-
tected using serial analysis of gene expression (SAGE)
[8,25,26] and there is evidence that a portion of the pa-
tient population contains a R179C mutation in GNAI2
known as the gip2 oncogene [13,24,27-29]. The R179C
mutations cause the Gαi2 enzyme to be GTPase defi-
cient, preventing signal termination, and causing Gαi2 to
be constantly active. Decreasing the expression or inhi-
biting the activation status of the gip2 oncogene has
anti-cancer effects in cell culture models [24,27]. The
gip2 oncogene was first described in OvCa, where it was
present in 3 of 10 non-epithelial endocrine tumors of the
ovary [28]. Further reports searching for gip2 showed no
gip2 in samples of 62, 18, 14, and 13 OvCa patients
[29-32]. More recent gip2 searches in other cancers have
also come up negative [27,33,34]. All of these data indicate
GNAI2 could be a central mediator in altering cellular
responses during cancer initiation and development [8].
We therefore conducted studies probing human patient
mRNA samples to determine the specific alterations of
GNAI2 in OvCa.
Methods
Origene human ovarian cDNA panels sequencing and
real-time PCR procedure
TissueScan™ Disease Tissue qPCR Human Ovarian Arrays
(OCAs) I-VI were obtained (OriGene Technologies,
Rockville MD) for GNAI2 gip2 mutations detection (Arg179
replaced with either Cys or His) and differential message ex-
pression relative to normal tissue GNAI2 levels. The panels
include carefully annotated but de-identified human patient
samples at various stages of OvCa development. Each panel
comes in duplicate: one panel for β-actin control (primers
supplied) and the second for our gene of interest. Our
GNAI2 primers were designed to complement the β-actin
primer efficiency through optimization utilizing an OvCa
cell line (SKOV3) to the recommended PCR parameters
for the Origene ovarian cDNA real-time PCR plates.GNAI2 mRNA relative quantification of ovarian tissue
samples by real-time PCR was performed using the compat-
ible Stratagene Mx4000 Real-time PCR System thermocycler
(Agilent Technologies, La Jolla, CA). OrigeneTissueScan
Disease Tissue qPCR Arrays (Origene Technologies, Inc.,
Rockville, MD) provide the normal and tumor ovarian
cDNA samples. Reactions were prepared according to
manufacturer’s instructions utilizing Maxima SYBR Green
qPCR Master Mix (Fermentas, Glen Burnie, MD) employ-






Real-time PCR for GNAI2 and β -actin parameters:
1 cycle→ 50°C 2 min (Activation).
1 cycle→ 95°C 5 min (Pre-soak).
40 cycles→ 95°C 15 sec, 60°C 1 min (Amplification).
1 cycle→ 95°C 1 min, 55°C 30 s, 95°C 30 s
(Dissociation).
Dissociation curve analysis followed each real-time
PCR procedure for confirmation of a single transcript
amplification, and products were visualized by 1% agarose
ethidium bromide gel electrophoresis to verify correct
amplicon size. Relative quantization values were calculated
utilizing the comparative threshold cycle method [35] with
normalization to β-actin and determined relative to the
normalized average non-cancerous tissue samples.
Gel purification was executed using 5 Prime Agarose
GelExact Mini Kit (Promega, Madison, WI) according to
manufacturer’s instructions. Purified GNAI2 products
were submitted for sequencing utilizing our GNAI2 for-
ward primer through Genewiz, Inc. (South Plainfield,
NJ). Prior to graphical representation, data was normal-
ized to gene-centric values, whereby the average global
expression value between normal and cancer (all data
points) was calibrated as zero. This was accomplished by




Datasets were acquired from The Cancer Genome Atlas
(TCGA) using normal ovarian and ovarian cancer data-
set values downloaded from cbioportal TCGA, Nature
2011, and GEO datasets [GSE:6008] [36], [GSE:14764]
[37], [GSE:29450] [38], [GDS:4066] [39], and [GDS:3297]
[40] from the NCBI. In GSE:6008, Hendrix et al. deter-
mined the significance of fibroblast oncogenesis driven by
Wnt in ovarian tumors using gene expression microarrays
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expression based ovarian cancer prognostic index [37]. In
GSE:29450, Stany et al. used laser captured microdissec-
tion samples and expression microarrays to analyze clear
cell histotype OvCa [38]. In GDS:4066 Spillman et al.
investigated changes in gene expression upon OvCa treat-
ment with estrogen using a mouse xenograft model [39].
In GDS:3297 Partheen et al. analyzed 54 stage III serous
ovarian adenocarcinoma tumor samples using mRNA ex-
pression oligonucleotide microarrays [40]. None of these
studies explicitly investigated GNAI2.
Statistical analysis
Statistics were calculated using nonparametric statistical
tests due to the greater accuracy of such tests in circum-
stances where Gaussian normality cannot be assumed,
and with only a ~5% error when used on Gaussian data
[41]. Kruskal-Wallis and Mann-Whitney rank-sum tests
were applied to all expression data unless otherwise
noted. In one instance, GSE:6008 staging data was tested
using an ANOVA under Gaussian assumptions due to the
data passing Anderson-Darling normality tests. Gaussian
statistics were used for histology data due to each staging
group’s indication of normality according to the Anderson-
Darling test. All data were analyzed using GraphPad Prism
and Microsoft Excel. When appropriate, data was normal-
ized to gene-centric values, whereby the average global ex-
pression value between normal and cancer (all data points)
was calibrated as zero.
Ethics approval
These studies were designated Not Human Research by
the Medical University of South Carolina Institutional
Review Board (Pro 24780) according to the Code of Federal
Regulations (45CFR46) due to anonymized handling and
retrospective analysis of data.
Results
Origene human ovarian cDNA panels sequencing
We began by investigating the human Origene ovarian
cancer array (OCA) using direct sequencing within the
coding region of GNAI2 transcripts. We found no muta-
tions within 192 samples. Analysis of the Cbioportal
database indicated one missense mutation in 489 sam-
ples (A114T). The 1000genomes database has a single si-
lent polymorphism in 1000 samples [42]. These all differ
from the known activating mutations of GNAI2: R179C
and Q205L [13].
Origene human ovarian cDNA panels real-time PCR
The low prevalence of gip2 is surprising as the gip2 mu-
tation is well characterized as transformative. This leaves
the possibility that there were changes in gene expres-
sion. We probed the OCA using qPCR for GNAI2. TheOCA demonstrated high variability in GNAI2 expres-
sion, but with the surprising result that the majority of
cancer patients underexpress GNAI2 (Figure 1A/C). The
mean for normal ovarian tissue was 0.42 ± 0.11 while the
mean in OvCa was -0.07 ± 0.04 (p < 0.004). These quali-
tative data revealed 141 individuals, or 85.5% of cancers,
underexpressed GNAI2 compared to the normal within
the Origene OCA. Seventy two samples (43.6%) under-
expressed below the -0.28 absolute minimum expression
threshold of normal patients.
Human GNAI2 transcriptome meta-analysis
To further confirm our results, we analyzed data from
the NIH GEO database. The Nature 2011 dataset con-
firms the trend and indicated 266 samples, or 84.4% of
cancer, were below the normal mean expression value of
0.38 ± 0.09 (p < 0.004) and 84 samples, or 26.7%, were
below the absolute minimum expression value of -0.21
from disease free patients (Figure 1B/D) [43]. All 10 can-
cer samples (100%) were found to underexpress with regard
to normal in GSE:29450, and 89 samples (89.9%) were
below normal GNAI2 message expression in GSE:6008.
The general trend in the magnitude of expression profiles
was reflected in the variance in expression from three of
the NCI60 cell lines. In this data set we found six OvCa
cell lines with a mean difference in GNAI2 expres-
sion of about one fold (Figure 1E/F). OVCAR4 cells
have the lowest GNAI2 expression (-0.39 fold) while
OVCAR8 had the highest (+0.23) and SKOV3 cells
were intermediate (-0.09).
GNAI2 expression was significantly reduced in cancer
patients (n = 505 reduced/589 total); however, the vari-
ability in human expression, cellular origin, or cancer
progression from other cancer arrays was of interest. We
analyzed cell type and staging data for GNAI2 in OvCa
patients utilizing diverse publicly available gene transcrip-
tion datasets with available GNAI2 expression levels.
Histology and staging analysis
In the GSE:6008 and GSE:14764 datasets, GNAI2 expression
was decreased in all types of OvCa but was distinct among
histological types of OvCa (Figure 2A/B). Clear cell and mu-
cinous cancers had the greatest reduction in message
amongst cancer cell types, with a mean of 2.91 ± 0.05 (p <
0.005) for clear cell and 2.92 ± 0.07 (p < 0.03) for mucinous
for a change of 0.37 fold versus 3.28 ± 0.05 (p < 0.01) for nor-
mal tissue samples. Endometrioid and serous carcinomas
were also depressed and significantly below normal samples.
Dataset GSE:29450 confirmed the trend of underexpression
of GNAI2 in ovarian cancer cells. In particular, all clear
cell cancer samples expressed below the mean expression
in non-cancerous tissue (p < 0.0001) (Figure 2C).
The relationship between GNAI2 and endocrine con-
trol was also of interest. We therefore analyzed GNAI2
Figure 1 GNAI2 message is suppressed in ovarian cancer. A. Rank order of GNAI2 expression of Origene OCA. Normal n = 27, Cancer n = 165.
B. GNAI2 expression from NIH NCBI TCGA, Nature 2011. Normal n = 8, Cancer n = 315. C. Scatter plot of A. * = cancer specific underexpression in
58% of patients. p < 0.004. D. Scatter plot of B. * = Nonparametric p < 0.003 Normal n = 8, Cancer n = 315. E. and F. GNAI2 expression of NCI60
samples. E. Data derived from GSE32374. F. Data derived from GSE2003. Expression presented as normalized gene centric values derived from
ΔΔCT with variance presented as 95% CI.
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pression varies significantly between ER+ versus ER- cells in
dataset GDS:4066 (Figure 2D). ER + cells expressed 7.73 ±
0.12 GNAI2 whereas ER- cells expressed 8.24 ± 0.08 (p <
0.006 between ER+ and ER-) for a decrease of 0.51 fold.
GNAI2 expression also correlates with tumor stage in-
dependent of cell histology (Figure 3). In GDS:3297 data-
set stage IIIB GNAI2 expression was -0.40 ± 0.20 and
significantly lower than IIIC expression of -0.11 ± 0.12 (p
< 0.04, Figure 3A). These results were paralleled in the
TCGA Nature 2011 dataset where IIIA OvCa had the low-
est mean expression of -0.47 ± 0.22 (p < 0.009) while late
stage cancer, IIIC and IV, had means of 0.02 ± 0.02 and
-0.02 ± 0.06, respectively (Figure 3B). In the GSE:6008
dataset, which uses a different scale than stage IIC
OvCa had the lowest expression of 9.38 ± 0.27 and stages
III, IIIC, and IV were statistically distinguishable via (p <
0.03 via Kruskal-Wallis ANOVA) (Figure 3C).
The presence of increased gene methylation and de-
creased message would suggest regulated gene silencing.We therefore wanted to determine if methylation was a
possible mechanism for the alterations in GNAI2, as op-
posed to upstream regulation of message. The Nature 2011
HM27 data revealed a correlation between GNAI2 gene
methylation and cancer staging although the means were
not statistically significant (Figure 3D). Methylation in-
creased with cancer stage and was especially pronounced
in several patients with class IIIC tumors. These data are
congruent with the GNAI2 promoter being regulated
through transcriptional gene control.
Transcriptome meta-analysis downstream of GNAI2
The consequence of downregulating GNAI2 leads to
disregulation of adenylyl cyclase, hyperaccumulation of
cAMP, thereby causing hyperactivation of CREB. Activation
of CREB then alters gene transcription of cAMP response
elements (CRE) leading to altered expression of CRE re-
sponsive genes including other transcription factors like
Fos and Myc as well as other oncogenes like cyclins and
Arf [44-46]. We therefore analyzed the available datasets
Figure 2 GNAI2 expression correlates with ovarian cancer tissue type. A. Data derived from GSE6008 normal n = 4, mucinous n = 13, clear
cell n = 8, endometrioid n = 37, serous n = 41. Nonparametric normal and clear p < 0.005, normal and mucinous p < 0.03, normal and endometrioid
p < 0.02, normal and serous p < 0.05. Expression is presented as HPRT1 normalized ΔΔCT. B. Data derived from GSE14764. Clear cell n = 2, endometrial
ovarian n = 7, serous n = 68. Kruskal-Wallis ANOVA p < 0.005. Expression is presented as Affymetrix MAS 5.0 signal intensity C. Data derived from
GSE29450. Normal n = 10. Clear Cell n = 10. Nonparametric p < 0.0001. Values reported as RMA signal intensity. D. GNAI2 expression correlates with
estrogen sensitivity. Data derived from GDS4066, ER + n = 7, ER- n = 8. Nonparametric p < 0.006. Values reported as RMA signal intensity.
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set GSE6008 indicated CREBL2, Fos, and Myc were
underexpressed (Figure 4). CREBL2 showed lowest ex-
pression in endometrioid ovarian cancer, and was found
to express below the normal mean of 3.66 ± 0.03 for
the following OvCa histotypes: clear cell at 3.25 ± 0.04
(p < 0.005), mucinous at 3.29 ± 0.03 (p < 0.004), endome-
trioid at 3.22 ± 0.03 (p < 0.003), and serous at 3.24 ± 0.02
mean expression (p < 0.002) (Figure 4A). Fos expressed
below the normal mean value of 4.31 ± 0.02 in all histo-
types as follows, with minimal expression demonstrated
in clear cell: clear cell at 3.38 ± 0.20 (p < 0.005), mucinous
at 3.71 ± 0.14 (p < 0.04), endometrioid at 3.43 ± 0.08 (p <
0.002), and serous at 3.56 ± 0.06 (p < 0.002) (Figure 4B).
Myc expression in ovarian cancers was lower than normal,
with the mean expression of 2.82 ± 0.13 (p < 0.005) for
clear, 3.35 ± 0.14 (p < 0.04) for mucinous, 3.38 ± 0.06 (p <
0.02) for endometrioid, 3.47 ± 0.06 (p < 0.07) for serous,
and 3.78 ± 0.04 for normal tissue (Figure 4C). This under-
expression is indicative of feedback gene repression due to
hyperactivation of the signaling pathway.
We found Cyclin A1, Cyclin D1 and Arf4L, which are all
downstream of GNAI2/cAMP/CREB, were overexpressed.Cyclin A1 was significantly overexpressed in both endome-
troioid, with a mean of 2.95 ± 0.09 (p < 0.027), and serous
3.19 ± 0.07 (p < 0.004) compared to normal 2.31 ± 0.07 in
dataset GSE:6008 (Figure 4D). Cyclin D1 was overexpressed
in comparison to normal in all histotypes (Figure 4E). Nor-
mal expression was 2.37 ± 0.07, compared to clear 2.89 ±
0.07 (p < 0.005), mucinous 3.26 ± 0.09 (p < 0.004), endome-
trioid 3.27 ± 0.06 (p < 0.002), and serous 3.10 ± 0.07 (p <
0.003). Arf4L overexpressed in clear cell, with a mean of
3.37 ± 0.03 versus normal’s 3.04 ± 0.04 (p = 0.004), and was
not significantly different from normal in mucinous, endo-
metrial or serous OvCa (Figure 4F). Both the histology and
staging data from GSE:6008 and Nature 2011, respectively,
showed that MAPK10 was decreased in expression com-
pared to normal which was consistent as its established
role is as a tumor suppressor [47]. MAPK10 had lowest
expression in serous cancer. Expression in clear cell was
2.96 ± 0.03 (p < 0.05), in mucinous 2.95 ± 0.04 (p < 0.02),
in endometrioid 2.919 ± 0.02 (p < 0.008), and in serous
2.84 ± 0.02 (p < 0.002). All of these were below the normal
expression of 3.12 ± 0.06 (Figure 4G). The Nature 2011
dataset yielded staging data correlations with MAPK10
expression where all stages of cancer underexpressed
Figure 3 GNAI2 expression correlates with tumor stage. A. Data derived from GDS3297. IIIB n = 9, IIIC n = 23. Nonparametric p < 0.04 B. Data
derived from TCGA, Nature 2011. Normal n = 8, IIA n = 2, IIB n = 4, IIC n = 8, IIIA n = 4, IIIB n = 14, IIIC n = 230, IV n = 53. Kruskal-Wallis p < 0.02.
Normal versus IIIA nonparametric p < 0.009, IIIB Nonparametric p < 0.006, IIIC Nonparametric p < 0.004, IV Nonparametric p < 0.007. C. Data derived
from GSE6008: stage III n = 2, IIIC n = 25, IV n = 5. Kruskal-Wallis ANOVA p < 0.03, Gaussian ANOVA p < 0.05, Gaussian III vs. IV p < 0.04, Gaussian
IIIC vs. IV p < 0.05. Anderson-Darling Normality for IIIC p > 0.6 and for IV p > 0.9. Stage IIIC and stage IV were also statistically different using a
parametric T-test. Expression is presented as HPRT1 normalized ΔΔCT. D. Methylation of GNAI2 gene correlates inversely with GNAI2 message
expression. Methylation values reported as beta values.
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Stage IIA expression was 0.15 ± 0.12 (p < 0.01), stage
IIB was -0.17 ± 0.18 (p < 0.005), stage IIC -0.15 ± 0.12
(p < 0.001), stage IIIA was 0.25 ± 0.40 (p < 0.03), stage
IIIB was 0.05 ± 0.14 (p < 0.002), stage IIIC was -0.03 ± 0.03
(p < 0.0001), and stage IV -0.17 ± 0.05 (p < 0.0001). In the
Nature 2011 dataset, Fos expression did not significantly
vary with staging (Figure 4I).
Discussion
We interrogated human OvCa for the presence of
polymorphisms and altered gene expression of GNAI2.
GNAI2 functions as a critical upstream regulator of OvCa
through suppression of cAMP, CREB activity, CRE func-
tion, and gene regulation. The increase in cAMP is neces-
sary for rapid growth and activation of CREB, promoting
angiogenesis, and protecting cancer cells from apoptosis
[48]. The gip2 activating polymorphisms in GNAI2 were
not present in 681 patient samples (n = 192 for Origene
and n = 489 from Nature 2011), reaffirming previous data
that the gip2 oncogene is rare in the human population.
However, when we aggregate our OvCa data with pub-
lished array data in datasets GSE:6008, Nature 2011, andGSE:29450, a consistent 86% of OvCa patients had de-
creased GNAI2 message levels with respect to normal.
Further characterization indicated a maximal decrease of
GNAI2 expression in clear cell phenotype. The Nature
HM27 arrays confirm methylation of the GNAI2 gene,
and Cbioportal data discounts the possibility of gene dele-
tion yielding false positives for methylation. Methylation
of GNAI2, which suppresses gene transcription, generally
increased with cancer stage and hypermethylation was
observed in 34.6% of patients with Stage IIIC tumors
(n = 353, mean = 0.09 ± 0.01).
GNAI2 message correlated with cancer stage and mean
message levels returned to normal (or overexpressed)
levels in most advanced cancer stages. These data indicate
GNAI2 alterations correlate with histologic type and can-
cer stage. In late stage cancer, cells could switch signal-
ing such that Gαi is uncoupled from the regulation of
cAMP/CREB dependent proliferation to CREB independ-
ent/migratory phenotypes [49,50]. G protein regulatory
(GPR)/Goloco motif-containing proteins, which uncouple
Gαi from GPCRs and prevent GDP release have also been
implicated in the regulation of cell division and differenti-
ation [51-54].
Figure 4 CRE effects in ovarian cancer. Data derived from GSE6008. Normal n = 4, mucinous n = 13, clear cell n = 8, endometrioid n = 37,
serous n = 41. A. Nonparametric normal and clear p < 0.005, normal and mucinous p < 0.004, normal and endometrioid p < 0.003, normal and
serous p < 0.002. B. Nonparametric normal versus endometrioid p < 0.03, normal and serous p < 0.004 C. Nonparametric normal and clear p < 0.005,
normal and mucinous p < 0.004, normal and endometrioid p < 0.002, normal and serous p < 0.003. D. Nonparametric normal and endometroioid
p < 0.027, normal and serous p < 0.004 E. Nonparametric normal and clear p < 0.005, normal and mucinous p < 0.004, normal and endometrioid
p < 0.002, normal and serous p < 0.003. F. Nonparametric normal and clear p = 0.004. G. Nonparametric normal and clear p < 0.05, normal and
mucinous p < 0.02, normal and endometrioid p < 0.008, normal and serous p < 0.002. H. Data derived from from NIH NCBI TCGA, Nature 2011. Normal
n = 8, stage IIA n = 3, IIB n = 4, IIC n = 16, stage IIIA n = 7, stage IIIB n = 21, stage IIIC n = 353, stage IV n = 79. Nonparametric normal and stage IIA
p < 0.01, normal and stage IIB p < 0.005, normal and stage IIC p < 0.001, normal and stage IIIA was p < 0.03, normal and stage IIIB p < 0.002, normal
and stage IIIC p < 0.0001, normal and stage IV p < 0.0001. I. Data derived from NIH NCBI TCGA, Nature 2011. Stage IIB n = 4, IIC n = 8, stage IIIA n = 4,
stage IIIB n = 14, stage IIIC n = 230, stage IV n = 53.
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from normal. The likely reason GNAI2 was not picked up
in many transcriptome studies was that most searches
emphasize genes with large changes in pathological expres-
sion (<200% or two fold). However, genes of high import-
ance can cause dramatic effects through small expression
variations, especially in G protein mediated amplification
cascades. As the body of data grows, more studies are alsofinding a link between cancer and aberrant GPCR/ER
expression and/or activation [11,55,56]. GNAI2 has the
unique ability to link GPCR and estrogen signaling
through its ability to suppress cAMP [57]. A decrease
in Gαi in cancer should increase the efficacy of estrogen
and GPCR mediated increases in cAMP production. This
may be of particular importance in cancers thought to
have an origin in estrogen mediated processes such as the
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gardless of the pathway, higher cAMP in cancer corre-
sponds to poorer prognosis [58]. Recent discoveries
regarding proteins such as NOTCH, Fos, and E-cadherin
also indicate that there is a subset of critical proteins that
can function as either oncogenes or tumor suppressors,
depending on cell type and/or tumor progression [59].
The decrease in GNAI2 in cancer patients suggests that
its functional role in humans is pleiotropic and that
GNAI2 can also function as a tumor suppressor depend-
ing on the cellular context.
Conclusions
GNAI2 was found to be underexpressed in the majority
of the ovarian cancer patient population. By being situ-
ated upstream of regulatory mechanisms that control
both proliferation and migration, GNAI2 could prove to
be a useful diagnostic indicator or potential therapeutic
target in ovarian cancer. However, our analyses did not
follow the clinical outcomes of the disease and therefore
more research must be done to determine if GNAI2 has
prognostic value. These data provide a strong rationale
for GNAI2 being a central player in ovarian epithelial
cell fate decisions during oncogenesis.
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